Skip to main
NTBL
NTBL logo

NTBL Stock Forecast & Price Target

NTBL Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Notable Labs Ltd's proprietary Predictive Precision Medicines Platform (PPMP) positions the company favorably within the clinical-stage therapeutics landscape by improving the accuracy of patient treatment predictions, which can accelerate therapeutic development timelines. The company's innovative approach not only enhances treatment efficacy for patients with cancer but also presents potential cost efficiencies for healthcare systems through more targeted therapies. Furthermore, Notable's advancements in predictive medicine align with growing market trends towards precision oncology, suggesting a strong viability and demand for their solutions in the evolving healthcare environment.

Bears say

Notable Labs Ltd is currently facing challenges related to its liquidity position and operational expenditures, which could hinder its ability to fund ongoing clinical trials and further development of its Predictive Precision Medicines Platform. Additionally, the company has reported a slower-than-anticipated patient enrollment in its studies, raising concerns about the timely execution of its therapeutic programs. Furthermore, competitive pressures in the precision medicine sector and the high cost of conducting clinical trials may undermine Notable's financial stability and investor confidence.

NTBL has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Notable Labs Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Notable Labs Inc (NTBL) Forecast

Analysts have given NTBL a Buy based on their latest research and market trends.

According to 2 analysts, NTBL has a Buy consensus rating as of Aug 1, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Notable Labs Inc (NTBL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.